Lördag 21 December | 13:07:13 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-08-28 08:00 Kvartalsrapport 2025-Q2
2025-05-29 N/A Årsstämma
2025-05-29 08:00 Kvartalsrapport 2025-Q1
2025-02-22 09:30 Bokslutskommuniké 2024
2024-11-21 - Kvartalsrapport 2024-Q3
2024-08-28 - Kvartalsrapport 2024-Q2
2024-05-30 - Kvartalsrapport 2024-Q1
2024-05-16 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2024-05-15 - Årsstämma
2024-02-27 - Extra Bolagsstämma 2024
2024-02-22 - Bokslutskommuniké 2023
2023-11-28 - Kvartalsrapport 2023-Q3
2023-08-30 - Kvartalsrapport 2023-Q2
2023-05-30 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2023-05-29 - Årsstämma
2023-05-29 - Kvartalsrapport 2023-Q1
2023-03-13 - Bokslutskommuniké 2022
2023-01-09 - Extra Bolagsstämma 2022
2022-11-28 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-06-02 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2022-06-01 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-02-23 - Bokslutskommuniké 2021
2021-11-22 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-18 - Kvartalsrapport 2021-Q1
2021-05-18 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2021-05-17 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-15 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2020-05-14 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-27 - Bokslutskommuniké 2019
2019-11-28 - Kvartalsrapport 2019-Q3
2019-08-29 - Kvartalsrapport 2019-Q2
2019-05-17 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2019-05-16 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-02-28 - Bokslutskommuniké 2018
2018-11-29 - Kvartalsrapport 2018-Q3
2018-08-30 - Kvartalsrapport 2018-Q2
2018-05-17 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2018-05-16 - Årsstämma
2018-05-16 - Kvartalsrapport 2018-Q1
2018-02-22 - Bokslutskommuniké 2017
2017-11-09 - Kvartalsrapport 2017-Q3
2017-10-06 - Extra Bolagsstämma 2017
2017-08-31 - Kvartalsrapport 2017-Q2
2017-05-12 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2017-05-11 - Årsstämma
2017-05-11 - Kvartalsrapport 2017-Q1
2017-02-23 - Bokslutskommuniké 2016
2016-10-27 - Kvartalsrapport 2016-Q3
2016-08-24 - Kvartalsrapport 2016-Q2
2016-06-09 - Extra Bolagsstämma 2016
2016-04-22 - Årsstämma
2016-04-22 - Kvartalsrapport 2016-Q1
2016-04-21 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2016-02-10 - Bokslutskommuniké 2015
2015-10-29 - Kvartalsrapport 2015-Q3
2015-08-13 - Kvartalsrapport 2015-Q2
2015-04-22 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2015-04-21 - Årsstämma
2015-04-21 - Kvartalsrapport 2015-Q1
2015-02-20 - Bokslutskommuniké 2014
2014-11-11 - Kvartalsrapport 2014-Q3
2014-08-21 - Kvartalsrapport 2014-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
LIDDS är ett läkemedelsbolag. Bolaget utvecklar läkemedelsprodukter baserade på en patentskyddad och kliniskt testad drug delivery-teknologi. Egenskaperna hos produkterna utgör grunden för LIDDS teknologiplattform för utveckling av injicerbara läkemedelsprodukter. LIDDS är förkortningen för Local Intelligent Drug Delivery System och bolaget har sitt huvudkontor i Uppsala.
2019-08-19 16:00:00

LIDDS has appointed Anja Peters Ohlsson as new CFO of LIDDS AB and member of the management team. Anja will succeed Bengt Norvik, who will leave his position in September following many years as CFO of the company.

Anja will assume her new role on September 2, 2019 and will report to CEO. Anja is 49 years old and holds a Major in Accounting and Finance from Uppsala University. Previous positions include CFO of Allenex/CareDx and ten years at E&Y. Anja has experience as CFO in listed companies both on Nasdaq Main Market and on Nasdaq First North.

- I am pleased to welcome Anja Peters as CFO of LIDDS. Anja has a strong financial and industrial background and will play a key role on the continued development of the company. I would also like to express my sincere gratitude to Bengt Norvik for his valuable efforts at LIDDS, says Monica Wallter, CEO of LIDDS.

In conjunction with Anja Peters assuming the role, current CFO Bengt Norvik will continue as CFO until Anja has taken office to ensure a stable and secure transition.

- I am delighted to have been appointed as new CFO for LIDDS. LIDDS is in an exciting and expansive phase, and I look forward to contributing to LIDDS development, says Anja Peters.

For additional information, please contact: 
Monica Wallter, CEO, LIDDS   +46 (0)737 07 09 22  monica.wallter@liddspharma.com

This information is such that LIDDS AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, at 16.00 CET on August 19, 2019.

About LIDDS AB (publ)
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid® is clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid® is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS shares (LIDDS) are listed on Nasdaq First North. Redeye AB, Certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com 

Attachment